Nasdaq

Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs ...

Opdivo plus low-dose Yervoy combination demonstrated long-term survival for patients with advanced non-small cell lung cancer across PD-L1 expression levels Median duration of response for patients ...
Nasdaq

Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival

Bristol-Myers Squibb Company today announced that Part 1 a of the Phase 3 CheckMate -227 trial evaluating Opdivo ® plus low-dose Yervoy ® met the co-primary endpoint of overall survival, demonstrating ...
Pharmabiz

Bristol-Myers' part 2 of phase 3 CheckMate -227 trial of Opdivo plus chemotherapy in patients with NSCLC fails to meet primary endpoint

Bristol-Myers Squibb, a global biopharmaceutical company, announced that part 2 of the phase 3 CheckMate -227 trial did not meet the primary endpoint of overall survival (OS) with Opdivo (nivolumab) ...